Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Erythropoietin Alfa
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : Erythropoietin Alfa
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : D614G variant LNP-encapsulated mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Globe Biotech's BANCOVID Elicits Neutralizing Antibody and Balanced Cellular Immune Response
Details : The candidate mRNA vaccine ‘BANCOVID’ is a LNP–encapsulated, nucleoside-modified mRNA–based vaccine that encodes the SARS-CoV-2 spike (S) glycoprotein stabilized in its prefusion conformation.
Product Name : Bancovid
Product Type : Vaccine
Upfront Cash : Inapplicable
September 30, 2020
Lead Product(s) : D614G variant LNP-encapsulated mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable